Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016 (2016), Article ID 3481578, 9 pages
http://dx.doi.org/10.1155/2016/3481578
Research Article

Prognostic Impact of mRNA Expression Levels of HER1–4 (ERBB1–4) in Patients with Locally Advanced Rectal Cancer

1III. Medizinische Klinik, Universitätsmedizin Mannheim, 68167 Mannheim, Germany
2Stratifyer Molecular Pathology GmbH, 50935 Köln, Germany
3Pathologisches Institut, Universitätsmedizin Mannheim, 68167 Mannheim, Germany
4Chirurgische Klinik, Universitätsmedizin Mannheim, 68167 Mannheim, Germany
5Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, 68167 Mannheim, Germany
6Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, 07747 Jena, Germany
7Klinik für Urologie, Universitätsmedizin Mannheim, 68167 Mannheim, Germany

Received 27 May 2016; Accepted 19 July 2016

Academic Editor: Haruhiko Sugimura

Copyright © 2016 Melanie Kripp et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. G. Zampino, R. Labianca, G. D. Beretta et al., “Rectal cancer,” Critical Reviews in Oncology/Hematology, vol. 70, no. 2, pp. 160–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Galandiuk, H. S. Wieand, C. G. Moertel et al., “Patterns of recurrence after curative resection of carcinoma of the colon and rectum,” Surgery Gynecology and Obstetrics, vol. 174, no. 1, pp. 27–32, 1992. View at Google Scholar · View at Scopus
  3. A. Martling, T. Holm, L. E. Rutqvist et al., “Impact of a surgical training programme on rectal cancer outcomes in Stockholm,” British Journal of Surgery, vol. 92, no. 2, pp. 225–229, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Sebag-Montefiore, R. J. Stephens, R. Steele et al., “Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial,” The Lancet, vol. 373, no. 9666, pp. 811–820, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Van Gijn, C. A. Marijnen, I. D. Nagtegaal et al., “Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial,” The Lancet Oncology, vol. 12, no. 6, pp. 575–582, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J.-P. Gérard, T. Conroy, F. Bonnetain et al., “Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203,” Journal of Clinical Oncology, vol. 24, no. 28, pp. 4620–4625, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J.-F. Bosset, L. Collette, G. Calais et al., “Chemotherapy with preoperative radiotherapy in rectal cancer,” The New England Journal of Medicine, vol. 355, no. 11, pp. 1114–1123, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. J. E. Tepper, M. O'Connell, D. Niedzwiecki et al., “Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of Intergroup 0114,” Journal of Clinical Oncology, vol. 20, no. 7, pp. 1744–1750, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. J. O'Connell, J. A. Martenson, H. S. Wieand et al., “Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery,” The New England Journal of Medicine, vol. 331, no. 8, pp. 502–507, 1994. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Rödel, U. Graeven, R. Fietkau et al., “Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial,” The Lancet Oncology, vol. 16, no. 8, pp. 979–989, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. S. Hong, B.-H. Nam, K.-P. Kim et al., “Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial,” The Lancet Oncology, vol. 15, no. 11, pp. 1245–1253, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. L. L. Gunderson, J. M. Jessup, D. J. Sargent, F. L. Greene, and A. Stewart, “Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes,” Journal of Clinical Oncology, vol. 28, no. 2, pp. 256–263, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. T. Price, H. M. Wilson, and N. E. Haites, “Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704,” European Journal of Cancer Part A, vol. 32, no. 11, pp. 1977–1982, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. K. M. Woods Ignatoski, T. Maehama, S. M. Markwart, J. E. Dixon, D. L. Livant, and S. P. Ethier, “ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity an human mammary epithelial cells,” British Journal of Cancer, vol. 82, no. 3, pp. 666–674, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Lu, G. Jiang, P. Blume-Jensen, and T. Hunter, “Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase,” Molecular and Cellular Biology, vol. 21, no. 12, pp. 4016–4031, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Ueno, H. Sakurai, S. Tsunoda et al., “Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells,” International Journal of Cancer, vol. 123, no. 2, pp. 340–347, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Radinsky, S. Risin, D. Fan et al., “Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells,” Clinical Cancer Research, vol. 1, no. 1, pp. 19–31, 1995. View at Google Scholar · View at Scopus
  18. T. Sasaki, T. Nakamura, R. B. Rebhun et al., “Modification of the primary tumor microenvironment by transforming growth factor α-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model,” American Journal of Pathology, vol. 173, no. 1, pp. 205–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Ho-Pun-Cheung, E. Assenat, C. Bascoul-Mollevi et al., “EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer,” International Journal of Cancer, vol. 128, no. 12, pp. 2938–2946, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. R.-D. Hofheinz, F. Wenz, S. Post et al., “Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial,” The Lancet Oncology, vol. 13, no. 6, pp. 579–588, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Bohmann, G. Hennig, U. Rogel et al., “RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods,” Clinical Chemistry, vol. 55, no. 9, pp. 1719–1727, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Koutras, K. T. Kalogeras, R. M. Wirtz et al., “Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) Validation Study,” Journal of Translational Medicine, vol. 13, no. 1, article 171, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Tramm, B. S. Sørensen, J. Overgaard, and J. Alsner, “Optimal reference genes for normalization of qRT-PCR data from archival formalin-fixed, paraffin-embedded breast tumors controlling for tumor cell content and decay of mRNA,” Diagnostic Molecular Pathology, vol. 22, no. 3, pp. 181–187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Toiyama, Y. Inoue, S. Saigusa et al., “Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery,” Clinical Oncology, vol. 22, no. 4, pp. 272–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Jakob, T. Liersch, W. Meyer, H. Becker, G. B. Baretton, and D. E. Aust, “Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy,” World Journal of Gastroenterology, vol. 14, no. 7, pp. 1060–1066, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. P. A. Fasching, K. Heusinger, L. Haeberle et al., “Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment,” BMC Cancer, vol. 11, article 486, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Marme, A. Schneeweiss, J. Aigner et al., “Abstract P3-06-08: Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer,” Cancer Research, vol. 72, no. 24, supplement, 2014. View at Publisher · View at Google Scholar
  28. B. Ingold Heppner, H.-M. Behrens, K. Balschun et al., “HER2/neu testing in primary colorectal carcinoma,” British Journal of Cancer, vol. 111, no. 10, pp. 1977–1984, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. L.-C. Conradi, H. Styczen, T. Sprenger et al., “Frequency of HER-2 positivity in rectal cancer and prognosis,” The American Journal of Surgical Pathology, vol. 37, no. 4, pp. 522–531, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Valtorta, C. Martino, A. Sartore-Bianchi et al., “Assessment of a HER2 scoring system for colorectal cancer: Results from a Validation Study,” Modern Pathology, vol. 28, no. 11, pp. 1481–1491, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Siena, A. Sartore-Bianchi, S. Lonardi, L. Trusolino, C. Martino, and K. Bencardino, “Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial,” in Proceedings of the ASCO Annual Meeting, suppl; abstr 3508, Chicago, Ill, USA, 2015.
  32. K. A. David, F. T. Unger, P. Uhlig et al., “Surgical procedures and postsurgical tissue processing significantly affect expression of genes and EGFR-pathway proteins in colorectal cancer tissue,” Oncotarget, vol. 5, no. 22, pp. 11017–11028, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. N. W. Liu, T. Sanford, R. Srinivasan et al., “Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma,” Clinical Cancer Research, vol. 19, no. 1, pp. 42–49, 2013. View at Publisher · View at Google Scholar · View at Scopus